Safety-Related Labeling Changes

Avoid coadministration of Zanubrutinib with moderate Cytochrome (CYP3A4) inducers. Narrow therapeutic index medicines that are metabolized by Cytochrome (CYP3A) and Cytochrome (CYP2C19) should be used with caution with Zanubrutinib

Trade Name

Brukinsa

Updated Section

2.3 Dosage Modifications for Drug Interactions

Month

Mar,2023